Claim 4. (Amended) The method of [Use according to] claim 3, characterized in that the impairment of hearing is a deep sound hearing impairment.

Claim 5. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the disturbance or illness of the inner ear is linked with a hydrops, particularly an endolymphatic hydrops.

Claim 6. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the disturbance or illness of the inner ear is Menière's disease.

Claim 7. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist is a peptide compound.

Claim 8. (Amended) The method of [Use according to] claim 7, characterized in that the peptide compound is a linear peptide, particularly propionyl-D-Tyr(Et)-Phe-Val-Asn-Abu-Pro-Arg-Arg-$NH_2$.

Claim 9. (Amended) The method of claim 1 [Use according to one of the claims 1 to 6], characterized in that the receptor antagonist is a non-peptidic, preferably non-peptidic, organic substance.

Claim 10. (Amended) The method of [Use according to] claim 9, characterized in that the organic substance is a benzazepin

derivative.

Claim 11. (Amended) The method of [Use according to] claim 10, characterized in that the benzazepin derivative is 5-dimethylamino-1-{4-(2-methyl-benzoylamino)-benzoyl}-2,3,4,5-tetrahydro-1H-benzazepin.

Claim 12. (Amended) The method of [Use according to] claim 9, characterized in that the organic substance is an indole derivative.

Claim 13. (Amended) The method of [Use according to] claim 12, characterized in that the indole derivative is 1-[4-(N-tert.-butyl carbamoyl)-2-methoxybenzene sulphonyl]-5-ethoxy-3-spiro-[4-(2-morpholinoethoxy)-cyclohexane]-indol-2-one fumarate.

Claim 14. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist can be administered orally and/or intravenously, particularly orally.

Claim 15. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor antagonist is used in a quantity of 0.1 to 50 mg/kg of body weight and per day.

Claim 16. (Amended) The method of claim 1 [Use according to one of the preceding claims], characterized in that the receptor